Back to results
US 9,801,854 B1Granted
Slow release formulations of cell cycle regulators and anti-cancer agents for local treatment of solid cancer
AssigneeUrogen Pharma Ltd.
InventorsDalit Strauss-Ayali, Gil Hakim, Marina Konorty, Astar Friedman
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for treating cancer of a body cavity, including specifically urinary tract cancer, by way of at least one cell cycle regulator, and at least one anti-cancer drug for local treatment; wherein the therapeutic agents are embedded in, and slowly released from, a biocompatible hydrogel composition.
Claims14
A method for treating a urinary tract cancer, comprising:
- first administering to a subject in need thereof a first composition comprising a thermoreversible hydrogel composition and a therapeutically effective amount of at least one cell cycle modulator selected from the group consisting of hydroxyurea, alternol, resveratrol, fluorodeoxyuridine, thymidine dinucleotide pTpT and Zidovudine, PD-0332991, LEE011, CINK4, Flavopiridol p276-00 and P1446A-05;
- and
- secondly administering to the subject a second composition comprising a thermoreversible hydrogel composition and a therapeutically effective amount of at least one chemotherapeutic agent selected from the group consisting of Mitomycin C, Apaziquone, Gemcitabine, Cisplatin, 5-FU (5-fluorouracil) Doxorubicin, Valrubicin, Epirubicin, Pirarubicin, and Methotrexate,
- wherein the administration of the first and second compositions is by local administration to the urinary tract,
- thereby treating the urinary tract cancer.
2 more elements
A method for treating a urinary tract cancer, comprising:
- first administering to a subject in need thereof a first composition comprising a thermoreversible hydrogel composition and a therapeutically effective amount of hydroxyurea;
- and
- secondly administering to the subject a second composition comprising a therapeutically effective amount of at least one chemotherapeutic agent selected from the group consisting of Mitomycin C, Cisplatin, Gemcitabine and doxorubicin,
- wherein the administration of the first and second compositions is by local administration to the urinary tract, thereby treating the urinary tract cancer.
1 more element
Dependencies are inferred from the claim text.